Targeted therapies

• Health & Medicine

NICE doesn’t recommend olaparib for patients with certain prostate cancers

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

13 September 2022

• Health & Medicine

New breast and lung cancer treatments approved in Scotland

3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer. 3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer.

19 January 2022

• Health & Medicine
• Science & Technology

Prising open the trap: Getting to grips with targeted cancer drug resistance

Cancer Research UK-funded scientists are using innovative techniques to understand how resistance to a targeted cancer drug is unfolding. Cancer Research UK-funded scientists are using innovative techniques to understand how resistance to a targeted cancer drug is unfolding.

10 January 2022

• Health & Medicine

Over 600 people in England set to benefit from innovative lung cancer treatment

More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence. More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence.

1 December 2021

• Health & Medicine

Three cancer drugs approved for NHS use in Scotland

Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected. Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected.

11 November 2021

• Health & Medicine

First targeted treatment approved for advanced prostate cancer on NHS in Scotland

The targeted drug olaparib has been approved for some people with a type of advanced prostate cancer on the NHS in Scotland. The targeted drug olaparib has been approved for some people with a type of advanced prostate cancer on the NHS in Scotland.

13 October 2021

• Health & Medicine

New drug available for rare thyroid cancer on NHS in England

The National Institute for Health and Care Excellence (NICE) has recommended the use of the drug selpercatinib (Retevmo) for some people in England with a type of advanced thyroid cancer. The National Institute for Health and Care Excellence (NICE) has recommended the use of the drug selpercatinib (Retevmo) for some people in England with a type of advanced thyroid cancer.

1 October 2021

• Health & Medicine

NHS lung cancer patients in England get early access to ‘breakthrough’ cancer drug

The Medicines and Healthcare products Regulatory Agency has approved the first-of-its-kind drug sotorasib for some people with non small cell lung cancer. The Medicines and Healthcare products Regulatory Agency has approved the first-of-its-kind drug sotorasib for some people with non small cell lung cancer.

10 September 2021

• Health & Medicine
• Science & Technology

Innovative cancer spinouts: 3 new projects get green light

The spin out companies are engineering viruses to seek and destroy cancer cells and using bacteria to break down the physical defences of tumours. The spin out companies are engineering viruses to seek and destroy cancer cells and using bacteria to break down the physical defences of tumours.

13 August 2021

• Health & Medicine

First treatment approved in England for advanced bile duct cancer

The National Institute of Health and Care Excellence (NICE) has approved the use of pemigatinib in adults with a rare type of bile duct cancer that has continued to advance or spread after initial chemotherapy. The National Institute of Health and Care Excellence (NICE) has approved the use of pemigatinib in adults with a rare type of bile duct cancer that has continued to advance or spread after initial chemotherapy.

22 July 2021

• Health & Medicine
• Science & Technology

ASCO 2021 news: follow-up treatments pave the way

One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented. One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented.

9 June 2021

• Health & Medicine

Three new cancer drugs approved for NHS in Scotland

The three latest SMC decisions will provide new treatment options for some adults with non small cell lung cancer, multiple myeloma and a rare type of lymphoma. The three latest SMC decisions will provide new treatment options for some adults with non small cell lung cancer, multiple myeloma and a rare type of lymphoma.

21 January 2021